Message from the CEO

Since our founding in 1939, Eiken Chemical has contributed to public health and the control of communicable diseases in Japan through the development of bacteria examination reagents (culture media) for infectious diseases. In various fields such as urinalysis, clinical chemistry, immunological, serological, and genetic examinations, we have developed the clinical examination reagents, medical equipment, and systems needed for medical care in each coming era, thereby contributing to the advancement of medical care and improvement of people’s health. Our fecal immunochemical test reagents and equipment for colorectal cancer screening examinations are now used extensively not only in Japan but also in a wide range of other countries all over the world. These products have made especially large contributions to early detection and reduced mortality for colorectal cancer.

Regarding the business environment surrounding Eiken Chemical, the promotion of regional comprehensive care systems is expected to expand in Japan due to factors such as diversification of medical care and nursing needs in the medical environment caused by the aging Japanese society. Overseas, developed countries have an increasing need for efficiency to keep medical costs under control, and preventive care is expanding as well. Emerging countries are seeking to establish and maintain medical infrastructure to suit their increasing populations and progressing economic development. In both types of countries, the role of clinical diagnostics is becoming increasingly important.

Eiken Chemical has established a new management framework known as EIKEN ROAD MAP 2030 based on the principles of the EIKEN WAY. By realizing our ideal state in 2030, we will continue protecting people’s health as a global clinical diagnostics company.

 

President & CEO
Yuji Segawa